DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Biopharmaceutical Manufacturing Market Report 2017-2021" report to their offering.
The efficacy and safety of biopharmaceuticals, coupled with their ability to address previously untreatable conditions, allows healthcare companies to command higher prices and margins for these drugs. Driven by their numerous advantages over conventional drugs, biopharmaceuticals today represent a big opportunity and represent more than 20% of the total global pharmaceutical sales. The current annual growth rate of biopharmaceuticals is also double that of conventional drugs, and growth is expected to remain robust for the foreseeable future. As a result of their rapid growth, many new players are entering this market and most current manufacturers are expanding their manufacturing capacities. Moreover, with the anticipated launch of a number of biosimilar drugs in the next five years, we expect a significant expansion in the global biopharmaceutical manufacturing capacity. We expect these trends to make biopharmaceutical manufacturing a very lucrative opportunity for investors and manufacturers.
The global biopharmaceutical manufacturing has been categorized on the basis of cell culture which includes mammalian cell culture and microbial cell culture. Currently, the largest number of biopharmaceutical products are manufactured using mammalian cell culture. Moreover, the mammalian-cell based products are more compatible with patients as these have been shown to cause minimum adverse reactions. As a result, there has been an increase in the mammalian based products over the past several years. Currently, mammalian cell culture holds a dominating share accounting for 56% in the total biopharmaceutical cell culture market. On the other hand, a significant growth has been observed in the microbial based products as well.
Biopharmaceuticals are Growing Faster than Small Molecule Drugs
Growth of Biosimilars will Push Volumes and Introduce New Players in
A Rich Biopharmaceutical Pipeline will Drive the Capacity Demand in
the Coming Years
Increasing Trends in Mergers and Acquisitions will Increase Redundant
Increasing Focus on Personalized Medicines and High Value Low Volume
Higher Titers will Reduce Capacity Demand
Growth in the Use of Cost Effective Disposable Technologies
Despite Sufficient Global Capacity, Its Uneven Distribution will
Continue to Spur Demand
- Biogen Idec
- Johnson & Johnson
- Merck & Co.
- Novo Nordisk
- Sanofi S.A
Key Topics Covered:
2 Research Methodology and Market Definitions
3 Executive Summary
4 Global Biopharmaceutical Market: Key Trends
5 Global Biopharmaceutical Market: Industry Performance
6 Regional Biopharmaceutical Market Analysis
7 Global Biopharmaceutical Manufacturing Industry
8 Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/zwr4zj/global